Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.

Source:http://linkedlifedata.com/resource/pubmed/id/14710235

Br. J. Cancer 2004 Jan 12 90 1 236-44

Download in:

View as

Triples

General Info

PMID
14710235